The most common starting doses were: 2mg weekly: This was the most frequent starting point, particularly for people assigned to higher target doses (8mg or 12mg)
J Clin Endocrinol Metab (1987) 64(1):1904
Regretfully, variability exists among analogs, complicating protocol standardization
HSS Journal
#Pharma #Obesity #WeightLoss #DrugDevelopment #ClinicalTrials #Roche #NovoNordisk #MetabolicHealth #HealthcareInnovation Source: Roche CT-388 mid-stage obesity trial Novo Nordisk zenagamtide mid-stage diabetes study To view or add a comment, sign in Treatment-Resistant Hypertension (TRH) Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight: The market dynamics for Treatment-Resistant Hypertension (TRH) is witnessing steady growth driven by the increasing prevalence of hypertension, growing burden of obesity, diabetes, and chronic kidney disease, improving diagnosis rates, and the introduction of novel antihypertensive therapies
Patients should focus on staying well-hydrated and may benefit from over-the-counter anti-diarrheal medications after consulting their healthcare provider
